Pediatric Allergic Rhinitis: When Meds Fall Short
Prospective cohort compares surgical vs medical management in refractory pediatric disease.
By
Kathryn Wighton
April 9, 2026
Clinical Scorecard: Pediatric Allergic Rhinitis: When Meds Fall Short
At a Glance
Category Detail
Condition Refractory Allergic Rhinitis in Pediatric Patients Key Mechanisms Inferior turbinate reduction improves sinonasal symptoms and quality of life. Target Population Pediatric patients aged 5 to 17 years with refractory allergic rhinitis. Care Setting Otolaryngology clinics and surgical settings.
Key Highlights
Surgery resulted in greater symptom score reductions at 1 and 3 months compared to medical therapy. 88% of surgical patients experienced complete disease regression at 1 month. Surgical patients reported reduced dependence on intranasal corticosteroids and oral antihistamines. Guideline-Based Recommendations
Diagnosis
Evaluate symptom persistence despite at least 3 months of intranasal corticosteroids and oral antihistamines. Management
Consider inferior turbinate reduction for patients with refractory symptoms. Monitoring & Follow-up
Assess outcomes using SN-5, OSA-18, and NOSE scales at baseline, 1 month, and 3 months. Risks
Potential selection bias due to non-randomized group allocation. Patient & Prescribing Data
Children aged 5 to 17 years with persistent allergic rhinitis symptoms.
Surgical intervention may provide better symptom relief compared to continued medical therapy.
Clinical Best Practices
Utilize patient-reported questionnaires for symptom assessment. Monitor for potential complications post-surgery, although none were reported in the study. References
